Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-3.35 | N/A | -299.28% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-3.35 | N/A | -299.28% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management's tone was defensive, reflecting the difficulties encountered. They reiterated their focus on future growth strategies.
Management acknowledged the challenges faced during the quarter.
They emphasized a commitment to long-term goals despite current setbacks.
Neurocrine Biosciences reported a significant loss in EPS, which contributed to a 6.1% drop in stock price. The lack of revenue figures and guidance adds uncertainty for investors. The management's defensive tone indicates they are aware of the challenges ahead but remain focused on long-term objectives.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BOSTON SCIENTIFIC CO